1 / 17

ESRD: State of the Art and Charting the Challenges for the Future

ESRD: State of the Art and Charting the Challenges for the Future. Beth Israel Deaconess and Harvard Medical School April 23 – 26, 2009. A teaching hospital of Harvard Medical School. Introductions. Welcome and Outline: Making a Difference Tom F. Parker lll Theodore I. Steinman.

sef
Download Presentation

ESRD: State of the Art and Charting the Challenges for the Future

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ESRD: State of the Art and Charting the Challenges for the Future Beth Israel Deaconess and Harvard Medical School April 23 – 26, 2009 A teaching hospital of Harvard Medical School

  2. Introductions • Welcome and Outline: Making a Difference • Tom F. Parker lll • Theodore I. Steinman A teaching hospital of Harvard Medical School

  3. William M. Bennett, MD Allan J. Collins, MD Richard J. Cronin, MD Francis L. Delmonico, MD Raymond Hakim, MD William L. Henrich, MD Alan Hull, MD: Honorary Chairman Prof. Norbert Lameire J. Michael Lazarus, MD Edmund Lowrie, MD Andrew S. Narva, MD Allen R. Nissenson, MD Eberhard Ritz, MD Steering CommitteeChairmen: Tom F. Parker and Theodore I. Steinman A teaching hospital of Harvard Medical School

  4. Sponsorswith appreciation • Platinum Level • Amgen • Genzyme A teaching hospital of Harvard Medical School

  5. Sponsorswith appreciation • Gold Level • Abbott Laboratories • American Renal Associates, LLC • Dallas Nephrology Associates, PA • Renal Ventures Management • Watson Pharmaceuticals A teaching hospital of Harvard Medical School

  6. Sponsorswith appreciation • Silver Level • AMAG Pharmaceuticals, Inc • NxStage • U. S. Renal • Fresenius Medical Care, NA • Contributors • B. Braun Medical, Inc. • DaVita A teaching hospital of Harvard Medical School

  7. Program Endorsements • American Society of Nephrology • National Kidney Foundation • Renal Physicians Association • International Society of Nephrology • European Dialysis and Transplant Association/European Renal Association A teaching hospital of Harvard Medical School

  8. Purpose of the meeting Explore medical and non-medical determinants of outcomes in the ESRD population • Medical: state of art lectures that cover the issues impacting ESRD • Non-medical: Impact on outcomes of government regulations and payment, guidelines, insurance companies, dialysis providers…. Use the information to plan new care initiatives and opportunities A teaching hospital of Harvard Medical School

  9. Knowledge has value only in so far as we can put it toward good purpose A teaching hospital of Harvard Medical School

  10. Eugene O’Neill, a marvelous and controversial playwright, observed once that “There is no present or future, only the past happening over and over again.” Did he have RRT in mind when saying this. A teaching hospital of Harvard Medical School

  11. The charge given to our speakers: • Determine the accomplishments in ESRD RRT over the past 20 years • Determine the impediments to improving RRT over the past 20 years • Understand the science to further improve outcomes • Understand the environment in which to apply the science • Outline the best approaches for care over the next 5 years A teaching hospital of Harvard Medical School

  12. The Setting • Our Milieu • 20% of facility patients die each year • A program that costs $34,000,000,000/year • $20,000 per patient per year in hospitalizations • Less than 20% rehabilitation • Survival results no better than colon ca. • 104,000 new ESRD patients – 2005 • 97,143 In Center HD • 6875 PD • 2424 Pre-emptive transplant A teaching hospital of Harvard Medical School

  13. Is this the best that we can do? A teaching hospital of Harvard Medical School

  14. Is the Problem? • The Science • The interpreter of the science • The nephrologist and other caregivers • The dialysis service provider • The patient • Demographics • Reluctance to participate in optimal care A teaching hospital of Harvard Medical School

  15. Is the Problem? • The payment system • Effect on innovation • Tenuous dependence • EPOGEN • Commercial payors • Medical Director conflicts of interest • Guidelines A teaching hospital of Harvard Medical School

  16. (Our) world is (what it is), not because of those who do bad things, but because of those who look on and do nothing."-Albert Einstein A teaching hospital of Harvard Medical School

  17. The Historical PerspectiveCo-Chairs: Drs. Mark Zeidel and Sushrat Waiker • 2:10 – 2:40 - What did we learn from the 1989 Dallas Conference on Mortality in Dialysis – Dr. Alan R. Hull A teaching hospital of Harvard Medical School

More Related